🔗 Visit the ClinicalTrials.gov page for NCT02623582
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Engineered T cells: the promise and challenges of cancer immunotherapy. | Nat Rev Cancer | 2016 | 1.51 |
| 2 | Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. | J Clin Invest | 2016 | 1.05 |
| 3 | Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy. | Clin Cancer Res | 2016 | 0.95 |
| 4 | CD123-Engager T Cells as a Novel Immunotherapeutic for Acute Myeloid Leukemia. | Mol Ther | 2016 | 0.78 |
| 5 | Chimeric antigen receptor T cell therapy in AML: How close are we? | Best Pract Res Clin Haematol | 2016 | 0.75 |